DOCS stock forecast, quote, news & analysis

DOCS sees MACD Histogram just turned negative

DOCS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 04, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 37 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 86%.

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for DOCS moved out of overbought territory on August 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 21 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.

The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DOCS as a result. In 60 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DOCS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

DOCS broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

DOCS moved above its 50-day moving average on August 07, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +5.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where DOCS advanced for three days, in 211 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. DOCS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.978) is normal, around the industry mean (7.171). P/E Ratio (30.452) is within average values for comparable stocks, (44.460). Projected Growth (PEG Ratio) (0.590) is also within normal values, averaging (1.499). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (7.669) is also within normal values, averaging (5.983).

The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DOCS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.